RecruitingNCT00373347
Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma
Sponsor
Stanford University
Enrollment
600 participants
Start Date
Nov 1, 2004
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Patients diagnosed with liver cancer based on biopsy or serum AFP level, associated with characteristic hypervascular liver tumors on triphasic spiral CT scan or MRI.
- Patients with non-cancer liver conditions such as cirrhosis, adenoma, cholangioma, or nodular hyperplasia.
- Patients with hepatitis B or hepatitis C viral infections not associated with liver cancer.
Exclusion Criteria1
- Patients will be excluded if, upon looking through their medical records, information required for data analysis are missing.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT00373347
Related Trials
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT066812334 locations
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
NCT050957141 location
Collection of Blood From Patients With Cancer
NCT000342161 location
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT0407530518 locations
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
NCT060919307 locations